Oral Sheep Milk-Derived Exosome Therapeutics for Cadmium-Induced Inflammatory Bowel Disease
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26073299 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Zhimin Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Animal Genetic Resources of Mongolia Plateau, College of Life Sciences, Inner Mongolia University, Hohhot 010020, China. Hauptthemen laut MEDLINE: Exosomes, Cadmium, Milk, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Inner Mongolia Autonomous Region "Jiebangguashuai" project of China, The Scientific and Technological Innovation 2030 - major project funding, 2024 Inner Mongolia University "Steed Plan" high-level talent funding.
Abstract (Originalsprache)
Cadmium (Cd) contamination in plants and soil poses significant risks to livestock, particularly sheep. Cd exposure often leads to severe gastrointestinal diseases in sheep that are difficult to treat. Milk-derived exosomes, particularly those from sheep milk (SM-Exo), have shown potential in treating gastrointestinal disorders, though their efficacy in Cd-induced colitis remains unclear. In this study, we investigated the therapeutic potential of SM-Exo in a Cd-induced colitis model. Hu sheep were exposed to Cd, and their fecal microbiota were collected to prepare bacterial solutions for fecal microbiota transplantation (FMT) in mice. The changes in gut microbiota and gene expression were analyzed through microbiome and transcriptomics. Our results showed that prior to treatment, harmful bacteria (e.g., Bacteroides and Parabacteroides) were increased in FMT mice. SM-Exo treatment increased beneficial bacteria, particularly Lachnoclostridium, and activated the Cyclic Adenosine Monophosphate (cAMP) pathway, upregulating genes like Adcy1, Adcy3, CREB, and Sst. These changes were linked to reduced Cd-induced cell death and alleviation of colonic inflammation. In conclusion, SM-Exo appears to be a promising treatment for Cd-induced colitis, likely through modulation of the gut microbiota and activation of the cAMP pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center for Animal Genetic Resources of Mongolia Plateau, College of Life Sciences, Inner Mongolia University, Hohhot 010020, China.
- The State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, College of Life Sciences, Inner Mongolia University, Hohhot 010020, China.
- Inner Mongolia Saikexing Institute of Breeding and Reproductive Biotechnology in Domestic Animal, Hohhot 011517, China.
ORCID-Profile: Xihe Li
Förderung
- Inner Mongolia Autonomous Region "Jiebangguashuai" project of China
- The Scientific and Technological Innovation 2030 - major project funding
- 2024 Inner Mongolia University "Steed Plan" high-level talent funding
- Inner Mongolia Autonomous Region “Jiebangguashuai” project of China
- The Scientific and Technological Innovation 2030
- 2024 Inner Mongolia University “Steed Plan”
Zitieren
APA
Wu, Z., Yan, S., Zhang, H., Ma, Z., Du, R., Liu, Z., Li, X., Cao, G., & Song, Y. (2025). Oral Sheep Milk-Derived Exosome Therapeutics for Cadmium-Induced Inflammatory Bowel Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073299
Vancouver
Wu Z, Yan S, Zhang H, Ma Z, Du R, Liu Z, et al. Oral Sheep Milk-Derived Exosome Therapeutics for Cadmium-Induced Inflammatory Bowel Disease. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073299
BibTeX
@article{Wu2025,
author = {Wu, Zhimin and Yan, Shuo and Zhang, Huimin and Ma, Zimeng and Du, Ruilin and Liu, Zhe and Li, Xihe and Cao, Guifang and Song, Yongli},
title = {Oral Sheep Milk-Derived Exosome Therapeutics for Cadmium-Induced Inflammatory Bowel Disease},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26073299}
}
EUVIMED